Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pegylated irinotecan for injection combined with temozolomide in glioblastoma
CTR20222017Phase 2Active
- Sponsor
- JenKem Technology
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Etirinotecan Pegol, temozolomide in glioblastoma (GBM), sponsored by JenKem Technology. Started Nov 2022; status: active.
02
Drugs
Etirinotecan Pegoltemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20222017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222017.